Therefore, we sought to determine the clinical relationship between S3Fand its receptors, neuropilin-2 (NP-2) and neuropilin-1 (NP-1) with EOC progression.We analyzed the immunohistological expression of S3F, NP-2, and NP-1 in clinicalspecimens of normal ovaries (N), benign cystadenomas (Cy), well-differentiatedadenocarcinomas (WD), poorly-differentiated adenocarcinomas (PD), inclusion cysts(IC), paraovarian cysts (PC), and fallopian tubes (FT). This evidence concerns the gene NRP1 and Wilson disease.